X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atrasentan (235) 235
male (130) 130
humans (120) 120
animals (105) 105
endothelin (86) 86
pyrrolidines - pharmacology (85) 85
index medicus (73) 73
endothelin receptor antagonists (71) 71
rats (61) 61
prostate cancer (57) 57
pharmacology & pharmacy (54) 54
endothelin-1 (44) 44
endothelin a receptor antagonists (43) 43
oncology (43) 43
prostatic neoplasms - drug therapy (38) 38
blood pressure - drug effects (37) 37
rats, sprague-dawley (36) 36
female (35) 35
pyrrolidines - therapeutic use (35) 35
antagonist (34) 34
receptor, endothelin a (34) 34
urology & nephrology (34) 34
middle aged (32) 32
endothelin-1 - metabolism (30) 30
aged (29) 29
expression (29) 29
cancer (26) 26
cells (26) 26
pyrrolidines - administration & dosage (26) 26
docetaxel (25) 25
hypertension (24) 24
men (24) 24
peripheral vascular disease (24) 24
prostatic neoplasms - pathology (24) 24
disease models, animal (23) 23
mice (23) 23
pharmacokinetics (23) 23
antineoplastic agents - therapeutic use (22) 22
cardiac & cardiovascular systems (22) 22
hypertension - physiopathology (22) 22
progression (22) 22
dose-response relationship, drug (21) 21
treatment outcome (21) 21
controlled-trial (20) 20
receptor, endothelin a - metabolism (20) 20
blockade (19) 19
bone neoplasms - secondary (19) 19
chemotherapy (19) 19
endothelin b receptor antagonists (19) 19
bosentan (18) 18
hypertension - chemically induced (18) 18
endothelin receptor (17) 17
time factors (17) 17
antimitotic agents (16) 16
antineoplastic agents (16) 16
blood-pressure (16) 16
clinical trials as topic (16) 16
endothelin-1 - antagonists & inhibitors (16) 16
research (16) 16
disease progression (15) 15
double-blind method (15) 15
adult (14) 14
aged, 80 and over (14) 14
growth-factor (14) 14
health aspects (14) 14
pyrrolidines - adverse effects (14) 14
pyrrolidines - pharmacokinetics (14) 14
abt-627 (13) 13
antineoplastic agents - pharmacology (13) 13
endothelin-1 - physiology (13) 13
phase-ii trial (13) 13
prostate-cancer (13) 13
receptor antagonist (13) 13
receptors, endothelin - metabolism (13) 13
refractory prostate-cancer (13) 13
survival (13) 13
zd4054 (13) 13
administration, oral (12) 12
albuminuria (12) 12
analysis (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
article (12) 12
bone neoplasms - drug therapy (12) 12
care and treatment (12) 12
clinical trials (12) 12
desoxycorticosterone (12) 12
diabetic nephropathy (12) 12
medicine, research & experimental (12) 12
metastasis (12) 12
ovarian-carcinoma cells (12) 12
receptor, endothelin b (12) 12
receptor, endothelin b - metabolism (12) 12
receptors, endothelin - physiology (12) 12
cloning (11) 11
drug therapy (11) 11
endocrinology & metabolism (11) 11
endothelin-1 - blood (11) 11
growth (11) 11
hemodynamics - drug effects (11) 11
kidney - drug effects (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 2019 - 2022
This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium... 
pharmacokinetics | endothelin receptor antagonist | dose‐finding | pharmacodynamics | diabetic nephropathy | dose-finding | ENDOCRINOLOGY & METABOLISM | DIABETIC-NEPHROPATHY | AVOSENTAN | Biomarkers - urine | Humans | Body Weight - drug effects | Diabetic Nephropathies - drug therapy | Diabetic Nephropathies - blood | Sodium - metabolism | Dose-Response Relationship, Drug | Drug Therapy, Combination - adverse effects | Diabetic Nephropathies - physiopathology | Renal Insufficiency - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Endothelin A Receptor Antagonists - adverse effects | Renal Insufficiency - complications | Renal Insufficiency - drug therapy | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Endothelin A Receptor Antagonists - therapeutic use | Diabetic Nephropathies - urine | Severity of Illness Index | Double-Blind Method | Endothelin A Receptor Antagonists - administration & dosage | Endothelin A Receptor Antagonists - pharmacokinetics | Biological Variation, Population | Renal Elimination - drug effects | Renal Insufficiency - metabolism | Albuminuria - prevention & control | Atrasentan - therapeutic use | Metabolic Clearance Rate - drug effects | Atrasentan - administration & dosage | Angiotensin Receptor Antagonists - therapeutic use | Atrasentan - adverse effects | Atrasentan - pharmacokinetics | Type 2 diabetes | Antimitotic agents | Medical research | Evaluation | Endothelin | Analysis | Diabetic nephropathies | Albumin | Medicine, Experimental | Antineoplastic agents | Creatinine | Kidneys | Sodium | Diabetes mellitus (non-insulin dependent) | Diabetes mellitus | Brief Reports | Brief Report
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1369 - 1376
Aims: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative,... 
diabetic kidney disease | endothelin receptor antagonist | randomized controlled clinical trial | atrasentan | personalized medicine | INHIBITION | ALBUMINURIA | PREDICTORS | HEART-FAILURE | ENDOCRINOLOGY & METABOLISM | Humans | Diabetic Nephropathies - drug therapy | Male | Renal Insufficiency, Chronic - complications | Renal Insufficiency, Chronic - drug therapy | Drug Therapy, Combination - adverse effects | Diabetic Nephropathies - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Adult | Endothelin A Receptor Antagonists - adverse effects | Female | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Endothelin A Receptor Antagonists - therapeutic use | Kidney - physiopathology | Precision Medicine | Severity of Illness Index | Kidney - drug effects | Double-Blind Method | Renal Insufficiency, Chronic - physiopathology | Disease Progression | Randomized Controlled Trials as Topic | Kidney Failure, Chronic - prevention & control | Kidney Failure, Chronic - complications | Atrasentan - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Atrasentan - adverse effects | Research Design | Type 2 diabetes | Antimitotic agents | Medical research | Endothelin | Chronic kidney failure | Diabetic nephropathies | Angiotensin | Clinical trials | Albumin | Medicine, Experimental | Antineoplastic agents | Risk factors | Creatinine | Renin | Nephropathy | Kidneys | Diabetes mellitus | Diabetes | Kidney diseases | Diabetes mellitus (non-insulin dependent) | Patients | Clinical Trial Design
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1829 - 1835
Aim: The SONAR trial uses an enrichment design based on the individual response to the selective endothelin receptor antagonist atrasentan on efficacy (the... 
diabetic kidney disease | endothelin receptor antagonist | precision medicine | randomized controlled clinical trial | atrasentan | KIDNEY-DISEASE | DAPAGLIFLOZIN | ALBUMINURIA | ENDOCRINOLOGY & METABOLISM | DIABETIC-NEPHROPATHY | EMPAGLIFLOZIN | Humans | Middle Aged | Hypertension - drug therapy | Male | Risk | Renal Insufficiency - prevention & control | Renal Insufficiency - epidemiology | Drug Therapy, Combination - adverse effects | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Diabetic Angiopathies - complications | Endothelin A Receptor Antagonists - adverse effects | Female | Renal Insufficiency - complications | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Endothelin A Receptor Antagonists - therapeutic use | Precision Medicine | Double-Blind Method | Diabetic Angiopathies - drug therapy | Antihypertensive Agents - therapeutic use | Diabetic Nephropathies - complications | Atrasentan - therapeutic use | Hypertension - complications | Diuretics - therapeutic use | Aged | Diabetic Nephropathies - epidemiology | Angiotensin Receptor Antagonists - therapeutic use | Atrasentan - adverse effects | Albumin | Endothelin | Kidney diseases | Natriuretic peptides | Creatinine | Brain natriuretic peptide | Kidneys | Sodium | Epidermal growth factor receptors | Diabetes mellitus | Blood pressure | Diabetes mellitus (non-insulin dependent) | Patients | Glomerular filtration rate | Clinical Trial Design
Journal Article
Journal Article
by Heerspink, Hiddo J L and Parving, Hans-Henrik and Andress, Dennis L and Bakris, George and Correa-Rotter, Ricardo and Hou, Fan-Fan and Hou, Fanfan and Kitzman, Dalane W and Kohan, Donald and Makino, Shinya and Makino, Hirofumi and McMurray, John J V and Melnick, Joel Z and Miller, Michael G and Miller, Alan and Miller, Steven and Pergola, Pablo E and Pergola, Pablo and Perkovic, Vlado and Tobe, Sheldon and Yi, Joo Hark and Yi, Tingting and Wigderson, Melissa and de Zeeuw, Dick and Elbert, Alicia and Vallejos, Augusto and Alvarisqueta, Andres and Maffei, Laura and Juncos, Luis and de Arteaga, Javier and Greloni, Gustavo and Farias, Eduardo and Zucchini, Alfredo and Vogel, Daniel and Cusumano, Ana and Santos, Juan and Fraenkel, Margaret and Gallagher, Martin and Davis, Tim and Acharya, Shamasunder and Cooke, Duncan and Suranyi, Michael and Roger, Simon and Toussaint, Nigel and Pollock, Carol and Chan, Doris and Stranks, Stephen and MacIsaac, Richard and Endre, Zoltan and Schmidt, Alice and Schmidt, Rebecca and Prager, Rudolf and Mayer, Gert and Warling, Xavier and Jadoul, Michel and Hougardy, Jean and Vercammen, Chris and Van Vlem, Bruno and Gillard, Pieter and Costa e Forti, Adriana and Borges, Joao Lindolfo and Santos Canani, Luis and Eliaschewitz, Freddy and Leite, Silmara and Fraige Filho, Fadlo and Paschoalin, Raphael and Moura Neto, Jose Andrade and Deboni, Luciane and de Lourdes Noronha, Irene and Cercato, Cintia and Prompt, Carlos Alberto and Zanella, Maria and Rassi, Nelson and D'Avila, Domingos and Milagres, Rosangela and Felicio, Joao and Pecoits Filho, Roberto and Riella, Miguel Carlos and Salles, Joao and Keitel, Elizete and Draibe, Sergio and Amodeo, Celso and Youmbissi, Joseph and Roy, Louise and Cournoyer, Serge and Jolly, Shivinder and Pichette, Vincent and Nesrallah, Gihad and Bajaj, Harpreet Singh and Khandwala, Hasnain and Aronson, Ronnie and Goluch, Richard and Tam, Paul and Rabbat, Christian and Bailey, Gordon and Chow, Stephen and Castillo, Alvaro and Danin Vargas, Alfredo and Gonzalez, Fernando and Munoz, Rodrigo and ... and SONAR Comm Investigators and SONAR Committees and Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1937 - 1947
Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | ENDOTHELIN | ALBUMINURIA | NEPHROPATHY | Humans | Middle Aged | Male | Diabetic Nephropathies - blood | Serum Albumin, Human - urine | Young Adult | Aged, 80 and over | Adult | Female | Diabetic Nephropathies - prevention & control | Endothelin A Receptor Antagonists - therapeutic use | Diabetic Nephropathies - urine | Glomerular Filtration Rate | Double-Blind Method | Endothelin A Receptor Antagonists - administration & dosage | Administration, Oral | Treatment Outcome | Creatinine - urine | Renal Insufficiency, Chronic - blood | Renal Insufficiency, Chronic - prevention & control | Atrasentan - therapeutic use | Creatinine - blood | Aged | Atrasentan - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Renal Insufficiency, Chronic - urine | Short term | Enrichment | End-stage renal disease | Renal function | Endothelin | Heart attacks | Peptides | Clinical trials | Cardiovascular disease | Transplantation | Retention | Randomization | Renin | Motivation | Hemoglobin | Blood pressure | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Heart failure | Urine | Creatinine | Enzymes | Kidneys | Epidermal growth factor receptors | Anemia | Diabetes mellitus | Health risks | Patients | Disease control | Glomerular filtration rate | Sodium | Angiotensin | Renal failure | Dialysis | Kidney diseases | Diabetes | Surface area | Potassium | Kidney transplantation | Long-term effects
Journal Article
ENDOCRINOLOGY, ISSN 0013-7227, 08/2019, Volume 160, Issue 8, pp. 1786 - 1796
Bone metastasis is a painful complication of advanced prostate cancer. Endothelin-1 is a tumor-secreted factor that plays a central role in osteoblast... 
ENDOTHELIN-A-RECEPTOR | PLACEBO | ANTAGONIST | ATRASENTAN | CAUSAL ROLE | GROWTH | MEN | ENDOCRINOLOGY & METABOLISM | ANIMAL-MODELS | MALE-MICE | ZIBOTENTAN ZD4054
Journal Article
Journal Article